News

A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Patients with allergic rhinitis report less satisfaction with oral antihistamines than intranasal corticosteroids or combination therapies.

Radhakrishnan emphasizes the importance of individualized IgAN care and how to best use currently available and emerging treatments.

A recent study indicates the potential benefits of consistent follow-up in diabetes through tele-education, teleconsultation, and digital data support.

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.

This interview from EADV highlights recent data from PRIME and PRIME2 on the effects of dupilumab (Dupixent) on itch and pain in prurigo nodularis.

Increases in short-term kidney function decline were observed following post-COVID-19 vaccination gross hematuria in individuals with IgA nephropathy.

The therapy was well-tolerated in the phase 2a ENV-IPF-101 trial, with mostly mild-to-moderate TEAEs related to treatment.

Investigators urge clinicians to support teenage patients with type 1 diabetes in managing their blood sugar and transitioning to adult care.

Subcutaneous Dpg-pol-cat significantly improved the quality of life and reduced medication use in adults with moderate to severe cat allergy.

In this interview, additional information on roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis was highlighted.

A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.

Peters emphasized how the new findings reinforce treatment strategies for chronic rhinosinusitis with nasal polyps.

Radhakrishnan breaks down the recent KDIGO IgAN guidelines and describes the evolving therapeutic landscape of IgA nephropathy.

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

This interview follows the FDA’s recent approval of Arcutis's roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis.

Donidalorsen demonstrates strong efficacy in patients switching from other HAE prophylactic treatments. Lumry discusses pivotal data after FDA approval.

The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.

The new therapy, marketed as Jascayd, previously demonstrated safety and efficacy in the phase 3 FIBRONEER-IPF trial.

In this analysis, investigators highlight the impact of the route of MTX administration on drug survival among patients with psoriasis.

Lumry discuses donidalorsen, the first FDA-approved, RNA-targeted therapy for hereditary angioedema.

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.

High intake of both sugar-sweetened beverages and low- or non-sugar-sweetened beverages was linked to greater MASLD risk.

Bhatt discussed the latest data from a post-hoc analysis of the BOREAS and NOTUS trials.

The investigative therapy for treatment-resistant hypertension resulted in a substantial reduction in ambulatory 24-hour average systolic blood pressure versus placebo.